CIMZIA Drug Profile

Summary for Tradename: CIMZIA

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for CIMZIA
Recent Clinical Trials:	See clinical trials for CIMZIA

See drug prices for CIMZIA

Recent Clinical Trials for CIMZIA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Janssen Research & Development, LLC	Phase 2
UCB Biopharma S.P.R.L.	Phase 1
Robert Flavell, MD, PhD	Phase 1

See all CIMZIA clinical trials

Pharmacology for CIMZIA

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CIMZIA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CIMZIA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	7,012,135	2021-06-06	DrugPatentWatch analysis and company disclosures
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	7,186,820	2021-09-10	DrugPatentWatch analysis and company disclosures
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	7,977,464	2028-06-18	DrugPatentWatch analysis and company disclosures
Ucb, Inc.	CIMZIA	certolizumab pegol	Injection	125160	7,012,135	2021-06-06	DrugPatentWatch analysis and company disclosures
Ucb, Inc.	CIMZIA	certolizumab pegol	Injection	125160	7,186,820	2021-09-10	DrugPatentWatch analysis and company disclosures
Ucb, Inc.	CIMZIA	certolizumab pegol	Injection	125160	7,977,464	2028-06-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CIMZIA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,016,338	2036-12-20	Patent claims search
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,028,940	2037-03-16	Patent claims search
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,052,389	2034-02-13	Patent claims search
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,086,072	2033-11-05	Patent claims search
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,111,968	2036-08-10	Patent claims search
Ucb, Inc.	CIMZIA	certolizumab pegol	For Injection	125160	10,124,038	2036-03-18	Patent claims search

International Patents for CIMZIA

Country	Patent Number	Estimated Expiration
Cyprus	1121173
Portugal	2230308
Hungary	230553
Poland	218516
Russian Federation	2303604
Spain	2600080

Supplementary Protection Certificates for CIMZIA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2019C/517	Belgium		PRODUCT NAME: CERTOLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/09/544/001-002 20091006
LUC00109	Luxembourg		PRODUCT NAME: CIMZIA - CERTOLIZUMAB PEGOL; AUTHORISATION NUMBER AND DATE: EU/1/09/544/001; EU/1/09/544/002 20091006
C01287140/01	Switzerland		PRODUCT NAME: CERTOLIZUMAB PEGOL; REGISTRATION NO/DATE: SWISSMEDIC 57856 07.09.2007
CA 2010 00010	Denmark
122010000027	Germany		PRODUCT NAME: CIMZIA - CERTOLIZUMAB PEGOL IN ALLEN DEM GRUNDPATENT ZU GRUNDE LIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/09/544/001-002 20091001
PA2010006,C1287140	Lithuania		PRODUCT NAME: CERTOLIZUMABUM PEGOLUM; REGISTRATION NO/DATE: EU/1/09/544/001, 2009-10-01 EU/1/09/544/002 20091001

Market Dynamics and Financial Trajectory for CIMZIA

Last updated: February 19, 2026

What is CIMZIA and its Therapeutic Indications?

CIMZIA (certolizumab pegol) is a biologic drug developed by UCB. It is a tumor necrosis factor (TNF) blocker used to treat inflammatory and autoimmune diseases. Its primary indications include:

• Rheumatoid arthritis (RA)
• Crohn’s disease
• Psoriatic arthritis
• Ankylosing spondylitis
• Ulcerative colitis

Marketed since 2009, CIMZIA competes with other TNF inhibitors such as Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab).

Market Landscape and Competitive Position

Global Market Size

The global TNF inhibitor market was valued at approximately $38 billion in 2022, with biologics constituting roughly 85% of the biologic immune-modulator segment. CIMZIA's share remains under 2% of this market but has grown steadily.

Market Segment	2022 Valuation	Growth Rate (CAGR 2022-2027)
TNF inhibitors	$38 billion	6.2%
CIMZIA share	~0.7% of TNF market	--

Key Competitors and Market Share

CIMZIA’s main competitors dominate the market:

• Humira: 45%
• Enbrel: 20%
• Remicade: 15%
• Cimzia: 2%
• Others: 18%

CIMZIA's lower share stems from late market entry and patent protections of competitors.

Patent Status and Biosimilar Impact

CIMZIA’s U.S. patent expired in 2029, with EU protections ending in 2028. Biosimilar versions could enter markets from 2028 onward, exerting price pressures and reducing revenue.

Financial Trajectory and Revenue Analysis

Revenue Trends

UCB reports CIMZIA revenues as follows:

• 2020: €1.0 billion (~$1.2 billion)
• 2021: €1.1 billion (~$1.3 billion)
• 2022: €1.2 billion (~$1.4 billion)

Growth trend reflects higher sales in North America and Europe, offsetting generic competition in other regions. CAGR from 2020-2022: 9.1%.

Key Drivers of Revenue

• Market penetration: Expansion in new indications such as Crohn’s disease and ulcerative colitis.
• Pricing strategies: Premium pricing justified by clinical efficacy.
• Patient adherence: Long-term treatment adherence in chronic conditions.

Cost Structure and R&D Investment

UCB’s R&D expenses for CIMZIA approximate €450 million annually, spent on:

• New indication development
• Biosimilar development
• Formulation improvements

Gross profit margins hover around 70%, with net margins near 20%, reflecting high fixed costs and moderate sales pricing.

Future Market and Revenue Projections

Key Factors Influencing Growth

• Market expansion: Launches in emerging markets such as Asia and Latin America.
• Indication expansion: Approval for additional diseases, including hidradenitis suppurativa.
• Biosimilar competition: Entry expected post-2028, likely leading to price reductions of 30-50%.

Revenue Forecast (2023-2027)

Year	Estimated Revenue	Assumptions
2023	€1.3 billion (~$1.5 billion)	Continued growth in established markets, biosimilar threat remains manageable.
2024	€1.4 billion (~$1.6 billion)	New indications and pipeline progress support growth.
2025	€1.5 billion (~$1.8 billion)	Biosimilar entry expected in late 2025, possibly impacting revenue.
2026	€1.4 billion (~$1.7 billion)	Price competition effects increase; growth stabilizes.
2027	€1.3 billion (~$1.6 billion)	Biosimilar competition intensifies, limiting growth.

Risks to Financial Trajectory

• Biosimilar pricing pressure reduces margins.
• Patent litigation prolongs exclusivity in key markets.
• Competition from oral small-molecule drugs (biosimilars or new class).

Strategic Considerations

• UCB emphasizes expanding CIMZIA’s label indications to sustain growth.
• Investment in biosimilar development signals diversification.
• Geographic expansion into emerging markets is crucial.

Key Takeaways

• CIMZIA's global sales grew modestly, with revenues approximating €1.2–€1.4 billion annually from 2020 to 2022.
• Market share remains limited due to late entry and strong competitors, but expansion in indications and geographies offers upside.
• Biosimilar competition expected from 2028 could halve price points, impacting revenues unless mitigated by new indications or market expansion.
• R&D investment remains high at roughly €450 million annually, focusing on pipeline expansion and biosimilar development.
• Long-term growth depends heavily on biosimilar market dynamics, patent protections, and the successful launch of new indications.

FAQs

Q1: When is CIMZIA's patent expiration in major markets?
A1: U.S. patents expired in 2029; EU protections end in 2028.

Q2: How might biosimilar entry affect CIMZIA’s revenue?
A2: Revenue could decline 30–50% post-2028 due to price competition and market share erosion.

Q3: What strategies does UCB employ to sustain CIMZIA’s market position?
A3: Expanding indications, geographic penetration, and biosimilar development.

Q4: What are CIMZIA's primary indications that drive revenue?
A4: Rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Q5: How does the competitive landscape impact CIMZIA’s outlook?
A5: Dominance of entrenched players and biosimilars restrict growth; innovation and indication expansion are critical.

References

1. UCB Group. (2022). Annual Report.
2. Evaluate Pharma. (2022). World Preview: 2022.
3. IQVIA. (2022). Market Dynamics for Biologics.
4. U.S. Patent and Trademark Office. (2023). Patent Expiry Dates for Certolizumab pegol.
5. Scrip Intelligence. (2022). Biosimilar Entry and Market Competition.